On September 28, 2023 KeYe Life Technologies reported KY1 injection preparation has completed all preclinical experiments and completed the clinical approval application of the US FDA (Press release, KeYe Life Technologies, SEP 28, 2023, View Source;article_id=85 [SID1234644611]). KY1 is a small molecule inhibitor of RNA helicase developed independently by the company. It is the first molecule of its kind (First-In-Class) and an innovative drug product transformed from the company’s independent scientific research.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!